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Pneumococcal carriage precedes pneumococcal disease,[1] so patients 
with invasive pneumococcal disease (IPD) have similar serotypes to 
those present in the nasopharynx during carriage.[2] The prevalence 
of pneumococcal carriage has been described as generally high in 
Africa, particularly in young children, but considerable variation 
between countries exists.[3] Some studies done in Africa reported a 
prevalence of >70% pneumococcal carriage in children <5 years of 
age before the use of conjugate vaccines.[4,5]
Pneumococcal conjugate vaccines (PCVs) have been widely used 
in high-income countries and provide effective protection against 
vaccine serotypes (VTs). Recently there has been an increase in 
the use of PCVs in low- and middle-income countries.[6] PCVs are 
currently part of the South African (SA) Expanded Programme on 
Immunisation (EPI-SA).[7] In 2009, SA was the first African country 
to introduce the 7-valent PCV (PCV7) for infants at 6, 14 and 
36 weeks of age, with a novel schedule aligned to the World Health 
Organization’s recommended EPI.[7,8] In 2011, PCV7 was replaced by 
PCV13,[8] with a catch-up programme for children aged <2 years and 
6 months.[8]
Although the introduction of PCVs caused a decline in the 
prevalence of VTs in children, pneumococcal carriage remains 
unchanged because of the concomitant increase in non-vaccine 
serotypes (NVTs).[3,9] Some of the most frequently carried NVTs 
are 6C, 11A, 15A/B/C, 21, 22F, 23A/B and 35F.[10] In addition 
to direct protection and prevention of pneumococcal disease in 
vaccinated children, unvaccinated children benefit from reductions of 
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Background. Pneumococcal carriage studies provide a baseline for measuring the impact of pneumococcal conjugate vaccines (PCVs). The 
advent of conjugate vaccines has led to reductions in vaccine serotypes (VTs) in pneumococcal carriage. However, increasing non-vaccine 
serotypes (NVTs) remain a significant concern, necessitating continued surveillance of serotypes in the 13-valent PCV vaccine (PCV13) era.
Objectives. To investigate pneumococcal carriage, serotype distribution and risk factors for pneumococcal colonisation among children 
presenting for routine immunisation at two clinics in Gauteng Province, South Africa (SA), 10 years after PCV introduction into the SA 
Expanded Programme on Immunisation (EPI-SA).
Methods. Nasopharyngeal swabs were collected from 322 healthy children aged between 6 weeks and 5 years at two clinic centres in 2014 
and 2016. Demographic data, risk factors for colonisation and vaccination details were recorded. The pneumococcal isolates were serotyped 
and tested for antimicrobial susceptibility.
Results. Pneumococci were isolated from 138/316 healthy children (43.7%) presenting for routine immunisation at two clinics. The 
median age was 8.3 months and the age range 1.4 months - 5 years. Carriage varied across the age groups: 6 - 14 weeks 35.5%, 9 months 
27.5%, 18 months 21.7%, and 5 years 15.2%. Risk factors significantly associated with pneumococcal colonisation included young age (9 - 
18 months (odds ratio OR 3.5; 95% confidence interval (CI) 1.9 - 5.9), type of dwelling (single room (OR 8.1; 95% CI 1.3 - 52.3) or informal 
dwelling (OR 2.4; 95% CI 1.2 - 4.5)) and Haemophilus influenzae carriage (OR 5.6; 95% CI 0.6 - 2.5). Of the 26 serotypes detected, 19F 
(10/121; 8.3%) was the most frequent. The most frequent NVTs were 23B (16/121; 13.2%), 15B/C (14/121; 11.6 %) and 35B (11/121; 8.2%). 
Children aged 9 months carried the highest proportion of NVTs (33/101; 32.7%). Penicillin non-susceptibility was observed in 20 NVT 
isolates (20/36; 55.6%) and 2 VT isolates (2/36; 5.6%).
Conclusions. The pneumococcal carriage prevalence described in our study varied across the age groups and was lower compared with 
other African studies that looked at pneumococcal carriage post PCV. The study gave insight into the common NVTs encountered at two 
immunisation clinics in Gauteng. Given that pneumococcal carriage precedes disease, common colonisers such as 15B/C and 35B may be 
sufficiently prevalent in carriage for expansion to result in significant disease replacement.
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pneumococcal disease by the reductions of pneumococcal carriage in 
those who have been vaccinated, leading to reduced transmission. [11] 
Surveillance of the prevalence of pneumococcal serotypes in a 
population is important, to study the impact of PCVs.[10]
Objectives
In this study, we investigated pneumococcal carriage, risk factors 
associated with colonisation, and the NVTs frequently encountered 
in infants and children presenting for routine immunisation at two 
clinics in Gauteng Province, SA, 10 years after PCV introduction into 
the EPI-SA.
Methods
Study design and setting
The study was conducted in the Department of Medical Microbiology, 
University of Pretoria/National Health Laboratory Service (NHLS), 
SA.
Study population
The study population comprised healthy children aged ~6, 10 and 
14 weeks, 9 and 18 months, and 5 years presenting for routine 
immunisation at the KT Motubatse Clinic and the Zola Community 
Clinic in Gauteng. Sampling took place from June to December 2014 
at the KT Motubatse Clinic and from June to December 2016 at the 
Zola Community Clinic. Nasopharyngeal swabs (CalgiSwab type 1; 
Spectrum, USA) were collected from 322 children whose parents or 
guardians had signed written informed consent in their preferred 
language. Epidemiological data were obtained using a questionnaire 
that included demographic characteristics, the number of siblings 
aged <5 years who lived in the house, whether the participants 
attended a day-care centre, smoking habits of family members who 
lived with the participants, and medical and vaccination history. 
In addition, the parents/guardians accompanying the participants 
were asked whether the child had had any illnesses during the past 
3 months.
Laboratory procedures
The swabs were placed in skim milk-tryptone-glucose-glycerin 
(STGG) and selectively cultured on 5% sheep blood agar (Diagnostic 
Media Products, NHLS, SA) containing 5 mg/mL gentamicin. The 
agar plates were incubated in 5% carbon dioxide overnight at 37oC to 
isolate Streptococcus pneumoniae, Staphylococcus aureus, Moraxella 
catarrhalis, Corynebacterium pseudodiptheriticum and Haemophilus 
influenzae. S. pneumoniae was identified using colony morphology, 
alpha haemolysis on blood agar and susceptibility to optochin 
(5  µg; Becton Dickinson Microbiology Systems, USA). The isolates 
were tested for antimicrobial susceptibility to chloramphenicol, 
tetracycline, cotrimoxazole, erythromycin, clindamycin and 
rifampicin (Davies Diagnostics, UK) by disc diffusion (Kirby-
Bauer disc method). Oxacillin discs (1 µg) (Davies Diagnostics) 
were used to screen for penicillin susceptibility. Oxacillin-resistant 
isolates were further tested using the E-test (Epsilometer test; 
BioMérieux, USA) (for penicillin and cefotaxime) to determine the 
minimum inhibitory concentration. The results were interpreted 
using the 2014 Clinical Laboratory Standards Institute guidelines. [12] 
Multidrug resistance was defined as non-susceptibility to three or 
more classes of antimicrobials. Oral penicillin breakpoints were used 
for the interpretation of penicillin results, i.e. susceptible ≤0.06 µg/
mL, intermediately resistant 0.12 - 1 µg/mL and resistant ≥2 µg/
mL. Intermediately resistant and resistant isolates were defined as 
non-susceptible. Of the 138 S. pneumoniae carriage isolates, 121 
(87.7%) retained viability and were serotyped with the Quellung 
method using serotype-specific antisera (Statens Serum Institute, 
Denmark) at the Centre for Respiratory Diseases and Meningitis, 
National Institute for Communicable Diseases. The isolates were 
also serotyped by triplex real-time polymerase chain reaction assay 
containing 38 sets of serogroup/serotype-specific primer pairs.
Statistical analysis
All data were captured in Epi Info 7 (Centers for Disease Control, 
USA) and exported to Microsoft Excel, 2016 version (Microsoft, 
USA). Data were analysed using Stata v15 (StataCorp, USA) and 
descriptive statistics including proportions and associated 95% 
confidence intervals (CIs). Potential risk factors including age, day-
care centre attendance, smoking habits of family members who lived 
with participants, illnesses in the past 3 months, method of cooking, 
carriage of S. aureus and H. influenzae, vaccination and type of 
dwelling were tested by cross-tabulation to assess association between 
variables, and subsequently by univariate logistic analysis. Factors 
that were found to be significantly associated with odds of carriage 
were included in a multivariable model to calculate the adjusted odds 
ratios (ORs).
Ethics approval
Ethics approval for the study was obtained from the Human Research 
Ethics Committee, University of Pretoria (ref. no. 268/2016).
Results
The study enrolled 322 children and infants in 2014 (n=96) and 
2016 (n=220) from two healthcare centres in Gauteng. Six children 
had more than five variables of demographic information missing, 
and their data were excluded from further analysis. Characteristics 
of the individuals who participated in the study and those who were 
colonised with S. pneumoniae are set out in Table 1.
Pneumococcal serotype distribution
Among the 121 pneumococci isolates that retained viability, 
26 serotypes were detected. 19F (10/121; 8.3%) was the most frequent 
PCV13 serotype. The most frequent NVTs were 23B (16/121; 13.2%), 
15B/C (14/121; 11.6%) and 35B (11/121; 8.2%). Overall, NVTs 
represented 81.8% of isolates (21/26; 81.8%) (Fig. 1). Four carriage 
isolates (4/121; 3.0%) were non-typeable by the Quellung method. 
There were 101 infants/children who were colonised with NVTs and 
20 infants/children who carried VTs. Children aged 9 months (Fig. 2) 
carried the highest proportion of NVTs (33/101; 32.7%) compared 
with the other ages (6 weeks 10.7%, 10 weeks 7.4%, 14 weeks 14.9%, 
18 months 19.8%, 5 years 13.9%) (Fig. 2). Children aged 14 weeks 
carried the highest proportion of VTs (8/20; 40.0%) compared with 
the other ages.
Risk factors associated with pneumococcal carriage
Risk factors not included in Table 2 showed no noticeable effect on 
pneumococcal colonisation. In the analysis, the following risk factors 
were statistically insignificant: attending a day-care centre, method 
of cooking, and co-colonisation with S. aureus. Children in the age 
group 9 - 18 months (OR 3.4; 95% CI 1.5 - 6.7) had an increased risk 
of pneumococcal colonisation compared with children aged 5 years 
(OR 2.8; 95% CI 1.2 - 6.4). Children living in single-room dwellings 
had an increased risk of pneumococcal colonisation (OR 8.5; 95% 
CI 1.3 - 52.3) compared with those living in houses, while those living 
in informal dwellings also had greater odds of colonisation (OR 2.4; 
95% CI 1.1 - 5.2) compared with those living in houses, keeping other 
factors constant (Table 2). Children colonised with H. influenzae had 
a significantly higher risk of carrying pneumococcus (OR 5.6; 95% 
145       February 2021, Vol. 111, No. 2
RESEARCH
Table 1. Characteristics of individuals who participated in the study at healthcare centres in Gauteng Province, South Africa,  
2014 and 2016
Characteristics
Children enrolled in the study 
(N=316), n (%)
Children colonised with Streptococcus 
pneumoniae (N=138), n (%)
Gender
Male 158 (50.0) 67 (48.5)
Female 147 (46.5) 68 (49.3)
Not known 11 (3.5) 3 (2.2)
Age group
~6 weeks - 14 weeks 153 (48.4) 49 (35.5)
9 months 61 (19.3) 38 (27.5)
18 months 63 (19.9) 30 (21.7)
5 years 39 (12.3) 21 (15.2)
Specimen type
Nasopharyngeal swabs All samples All samples
Vaccination
Yes 267 (84.5) 116 (84.1)
No 47 (14.9) 21 (15.2)
No vaccination records 2 (0.6) 1 (0.7)
Previous illnesses*
Yes 97 (30.7) 39 (28.3)
No 193 (61.1) 92 (66.7)
No record 13 (4.1) 7 (5.1)
Day-care attendance
Yes 71 (22.4) 35 (25.4)
No 232 (73.2) 102 (73.9)
No data 13 (9.4) 1 (0.7)
Siblings <5 years
Yes 195 (61.7) 86 (62.3)
No 101 (32.0) 47 (34.1)
No data 20 (6.3) 6 (4.4)
Exposure to smoking
Yes 192 (60.7) 44 (31.9)
No 115 (36.4) 83 (60.1)
No data 9 (2.9) 1 (7.7)
*Previous illnesses included influenza, chicken pox, diarrhoea, teething, fever, bronchitis, eczema, fits, jaundice, meningitis, pneumonia, sinusitis and stomach aches.
Table 2. Risk factors associated with pneumococcal carriage (univariate and multivariate analysis) in individuals from Gauteng 
communities, South Africa, June - December 2014 and 2015
Risk factors
                            OR (95% CI)
Univariate Multivariable p-value
Age
6 - 14 weeks Ref† Ref
9 - 18 months 3.5 (2.0 - 6.2) 3.4 (1.9 - 5.9) <0.001*
5 years 2.8 (1.2 - 6.4) 2.5 (1.1 - 5.5) 0.024*
Day-care attendance
Yes 1.23 (0.67 - 2.3) 0.66
Type of dwelling
Single room 8.3 (1.3 - 52.7) 8.5 (1.3 - 52.3) 0.025*
Shack (informal dwelling) 1.8 (1.0 - 3.3) 2.4 (1.2 - 4.5) 0.010*
Method of cooking
Electric stove 1
Paraffin stove/gas stove 0.63 (0.2 - 2.4) 0.501
Haemophilus influenzae isolated in children carrying pneumococci 5.3 (2.73 - 10.3) 5.6 (0.6 - 2.5) <0.001*
Staphylococcus aureus isolated in children carrying pneumococci 1.2 (0.68 - 2.4) 0.642
OR = odds ratio; CI = confidence interval.
*Statistically significant.
†Reference, analysis based on pneumococcal carriage of 138 children.
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CI 0.6 - 2.5) compared with children who did not carry H. influenzae, 
also keeping other factors constant.
Antimicrobial susceptibility profiles of the  
S. pneumoniae nasopharyngeal isolates
Seventy-one isolates (71/138; 51.5%) were non-susceptible to one or 
more antimicrobial classes using the disc diffusion method. Of the 
121 serotyped isolates screened for penicillin susceptibility using 
oxacillin discs, 36 (36/121; 29.8%) were resistant to oxacillin. Twenty 
NVT isolates (20/36; 55.6%) and 2 VTs (2/36; 5.6%) were non-
susceptible to penicillin. All the NVT (29/36; 80.5%) and VT (7/36; 
19.4%) isolates were susceptible to cefotaxime (Table 3). Multidrug 
resistance was observed in 15B/C (1/121; 0.8%) and 19F (1/121; 
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Fig. 1. Non-PCV13 and PCV13 serotypes in the children (N=121) who participated in the study at two healthcare centres in Gauteng Province, South Africa, 
2014 and 2016. (PCV13 = 13-valent pneumococcal conjugate vaccine).
Table 3. Antimicrobial susceptibility among the vaccine and non-vaccine serotypes of pneumococcal isolates from children 
presenting at two clinics in Gauteng Province, South Africa, 2014 and 2016
Antimicrobial agents
Total N=121, n (%)*
                   Non-PCV13 serotypes PCV13 serotypes
Susceptible Non-susceptible Susceptible Non-susceptible
Penicillin†,‡ 9 (25.0) 20 (55.6) 5 (13.8) 2 (5.6)
Cefotaxime† 29 (80.5) 0 (0) 7 (19.4) 0 (0)
Cotrimoxazole 55 (45.5) 46 (38.0) 12 (9.9) 8 (6.6)
Erythromycin 95 (78.5) 6 (8.5) 18 (14.9) 2 (2.8)
Clindamycin 98 (80.1) 3 (4.2) 20 (16.5) 0
Tetracycline 98 (80.1) 3 (4.2) 20 (16.5) 0
MDR                     1 (0.8)                    1 (0.8)
PCV13 = 13-valent pneumococcal conjugate vaccine; MDR = multidrug resistant.
*Antimicrobial susceptibility of the serotyped isolates.
†These are the isolates (n=36) that were resistant to oxacillin and were further screened for minimum inhibitory concentration of penicillin and cefotaxime susceptibility.
‡Breakpoints used for penicillin were susceptible (≤0.06 µg/mL), intermediately resistant (0.12 - 1 µg/mL) and resistant (≥2 µg/mL) according to the Clinical and Laboratory Standards Institute 
guidelines. Intermediately resistant and resistant to penicillin were defined as non-susceptible.
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(isolates lost viability before they could be 
serotyped).
Discussion
This study reports the prevalence of 
pneumococcal carriage, risk factors 
associated with pneumococcal carriage, 
antimicrobial susceptibility of the carriage 
isolates and the common NVTs in healthy 
infants and children presenting for routine 
immunisation at two healthcare clinics in 
Gauteng. In our study, 43.7% of infants and 
children aged ≤5 years were colonised with 
pneumococcus. This is an interesting age 
group in which to study nasopharyngeal 
carriage, because they constitute a major 
reservoir and source of transmission, and are 
at high risk of pneumococcal disease.[13] The 
pneumococcal carriage prevalence obtained 
in this study was slightly lower compared 
with some carriage studies conducted in 
sub-Saharan Africa post-PCV.[3] Although 
the reported carriage prevalence differed 
between the age groups of the children in 
our study, pneumococcal carriage usually 
decreases with increasing age, as has been 
reported in six African studies that found 
the youngest children to have the highest 
pneumococcal carriage prevalence.[3] Other 
similar studies in African countries have also 
reported decreasing pneumococcal carriage 
with increasing age of healthy children.[3,14-16]
Pneumococcal carriage prevalence was high 
(66.7%) in children who reported no previous 
illness (influenza, diarrhoea, fever, jaundice, 
sinusitis, meningitis or pneumonia) during 
the 3 months prior to their enrolment in 
the study. These findings contrasted with 
studies looking at similar populations that 
reported higher pneumococcal carriage in 
children who had respiratory tract infections 
during the previous 3 months.[16-18] The 
low pneumococcal carriage of children 
reporting previous illness in our study 
could be attributed to recent treatment with 
antibiotics.
PCVs prevent pneumococcal disease 
by reducing pneumococcal carriage of 
VTs. Moreover, the impact of PCVs on 
nasopharyngeal carriage is considered 
to be a predictor of vaccine efficacy.[19] 
Approximately 80% of the children who 
were colonised with pneumococcus had 
been vaccinated and had completed the 
specific dose for their age. Although high 
vaccine coverage was observed in our study, 
a high proportion of NVTs was reported, 
highlighting the importance of monitoring 
nasopharyngeal carriage of serotypes not 
included in the vaccine. In our study, the 
majority of children who were colonised 
with pneumococcus were harbouring NVTs. 
In addition, our study found increased NVT 
pneumococcal colonisation, as recently 
reported by other studies.[20,21] The most 
common NVTs observed in this study have 
been reported in other studies following 
PCV administration.[22,23] Dagan et al.[23] 
reported NVTs (15A, 15B/C, 16F, 23A, 
35B) with 15B/C significantly higher in 
children vaccinated with PCV13. Clinically 
significant NVTs identified in SA cases of 
IPD post PCV13 in 2014 included 8, 12F, 
16F, 35B/35D and 15B/C, of which 35B 
and 15B/C were commonly encountered in 
our study.[24] Serotype 15B was commonly 
described in our isolates, and was also among 
the predominant serotypes 7 years ago in an 
SA community study looking at temporal 
changes in pneumococcal colonisation of 
children aged <2 years.[25] Some of these 
common NVTs identified in our study have 
low potential to cause disease.[26] However, 
in vulnerable populations these serotypes 
can still cause disease.[24] An increasing 
prevalence of some of these serotypes 
therefore warrants ongoing surveillance 
post vaccination. Risk factors significantly 
associated with pneumococcal carriage in 
this study included type of dwelling, young 
age, and carriage of H. influenzae. Our study 
did not find a significant association of 
day-care attendance with pneumococcal 
colonisation (although children attending 
a day-care centre had 23% higher risk 
compared with those who did not); 
however, other studies have reported that 
day-care centre attendance is associated 
with an increased risk of pneumococcal 
colonisation.[27,28] It is suggested that this 
increased risk is due to increased exposure to 
children who are colonised and even to those 
who may have pneumococcal disease. [29] 
Among Aboriginal children and adults in 
Western Australia, pneumococcal carriage 
was significantly associated with individuals 
living in remote areas and younger 
individuals,[29] comparable to the findings 
in our study. Increased pneumococcal 
colonisation as result of the type of dwelling 
(remote areas) may be attributed to exposure 
from the community, since these settlements 
are densely populated. Furthermore, the 
latter study also reported pneumococcal 
carriage associated with co-colonisation 
with H. influenzae, which was also observed 
in our study. In our study, a high proportion 
of NVTs showed non-susceptibility to 
penicillin. This contrasts with a study of 
infants at birth in Drakenstein near Cape 
Town, SA, in which PCV13 serotypes 
were more commonly non-susceptible to 
penicillin than NVTs.[20] The low propor-
tion of non-susceptible PCV13 serotypes 
observed may have been because of PCV, as 
suggested by other studies.[30,31]
 



















Age of the infants/children
Fig. 2. Distribution of vaccine and non-vaccine serotypes in each age group of children (N=121) 
presenting for immunisation at two healthcare centres in Gauteng, South Africa, 2014 and 2016.
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Study limitations
The study had several limitations, including a limited sample size 
for comprehensively studying the epidemiology of pneumococci, 
and the findings obtained therefore do not reflect the overall 
pneumococcal carriage prevalence in the two township communities. 
The recruitment process may have been biased, which resulted in 
there being more children in the 6 - 14 weeks age group. Further 
studies are recommended.
Conclusions
The study found that 43.7% of enrolled children were colonised with 
pneumococci. Young age, type of dwelling and carrying H. influenzae 
increased the risk of being colonised with pneumococci. We 
also describe an increased non-PCV13 serotype pneumococcal 
colonisation, as has been anticipated and largely described in other 
studies. The increased non-PCV13 serotypes obtained from the 
study highlight the importance of pneumococcal colonisation studies 
post PCV. Of equal importance, given that pneumococcal carriage 
precedes disease, common colonisers such as 15B/C and 35B may be 
sufficiently prevalent in carriage for expansion to result in significant 
disease replacement.
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